Management of hepatitis C patients with decompensated liver disease.

Abstract

Little is known about the tolerance and effectiveness of novel oral direct acting antivirals (DAA) in hepatitis C patients with decompensated cirrhosis. To examine the studies relevant to the treatment of hepatitis C virus(HCV)-related decompensated liver disease, we performed computer-based searches for English articles between 1947 and August 2015. Fourteen articles including HCV patients with decompensated cirrhosis were reviewed. The combinations of ledipasvir(LDV)/sofosbuvir(SOF)/ribavirin(RBV) for 12 weeks, or daclatasvir/SOF/RBV for 12 weeks are safe and effective for HCV genotype 1 or 4 infection, and daclatasvir/SOF/RBV for 12 weeks or SOF/RBV for 24 weeks might be effective and safe for HCV genotype 2 or 3 infection. In conclusion, current evidence supports the use of all oral DAA regimens in HCV patients with decompensated cirrhosis.

• Authors: Ching-Sheng Hsu, Jia-Horng Kao
• Journal: Expert review of gastroenterology & hepatology (Expert Rev Gastroenterol Hepatol) Vol. 10 Issue 6 Pg. 679-88 (Jun 2016) ISSN: 1747-4132 [Electronic] England
• PMID: 26782619 (Publication Type: Journal Article, Review)

Chemical References

• Antiviral Agents

Topics

• Antiviral Agents (adverse effects, therapeutic use)
• Drug Therapy, Combination
• Genotype
• Hepacivirus (drug effects, genetics, growth & development)
• Hepatitis C (complications, diagnosis, drug therapy)
• Humans
• Liver Cirrhosis (diagnosis, surgery, virology)
• Liver Transplantation
• Patient Selection
• Recurrence
• Risk Factors
• Treatment Outcome